Comparisons

Semaglutide vs. Tirzepatide: Head-to-Head Comparison of GLP-1 Medications

GLP-1 Companion · 9 min read

Semaglutide and tirzepatide represent the current gold standard in incretin-based therapies. Semaglutide is sold under the brand names Ozempic (for type 2 diabetes) and Wegovy (for weight management). Tirzepatide is sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight management). While both target the GLP-1 receptor, tirzepatide adds a second mechanism that sets it apart.

Mechanism of Action: Single vs. Dual Agonist

Semaglutide: GLP-1 Receptor Agonist

Semaglutide mimics the naturally occurring hormone glucagon-like peptide-1 (GLP-1). When it binds to GLP-1 receptors in the brain, pancreas, and gut, it slows gastric emptying, reduces appetite, enhances insulin secretion in response to meals, and suppresses glucagon release. The net effect is lower blood sugar, reduced hunger, and significant weight loss over time.

Tirzepatide: Dual GIP/GLP-1 Receptor Agonist

Tirzepatide activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP is another incretin hormone involved in glucose metabolism and energy balance. By engaging both pathways, tirzepatide may produce stronger appetite suppression, greater fat mobilization, and improved insulin sensitivity compared to GLP-1 activation alone.

Clinical Trial Data: Weight Loss

Both medications have been studied in large, rigorous clinical trial programs. The key weight loss trials are the STEP program (semaglutide) and the SURMOUNT program (tirzepatide).

Semaglutide Results (STEP Trials)

• STEP 1: Patients without diabetes lost an average of 14.9% of body weight at 68 weeks (2.4 mg dose) vs. 2.4% with placebo.
• STEP 2: Patients with type 2 diabetes lost 9.6% of body weight at 68 weeks.
• STEP 3 (with intensive behavioral therapy): Average weight loss reached 16% at 68 weeks.
• STEP 5 (two-year data): Weight loss of approximately 15.2% was sustained through 104 weeks.

Tirzepatide Results (SURMOUNT Trials)

• SURMOUNT-1: Patients without diabetes lost 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) of body weight at 72 weeks. Over 57% of participants on 15 mg lost ≥20% of body weight.
• SURMOUNT-2: Patients with type 2 diabetes lost up to 14.7% of body weight at 72 weeks.
• SURMOUNT-3 (with intensive lifestyle intervention): Average weight loss reached 26.6% at the highest dose.
• SURMOUNT-4 (withdrawal study): Patients who continued tirzepatide maintained weight loss; those switched to placebo regained approximately 14% over 88 weeks, confirming that discontinuation reverses outcomes.

Direct Head-to-Head: SURMOUNT-5

The SURMOUNT-5 trial (published in NEJM, 2025) is the first randomized head-to-head comparison of the two drugs. Tirzepatide achieved −20.2% weight loss (22.8 kg) versus −13.7% (15.0 kg) for semaglutide 2.4 mg over 72 weeks (P<0.001). Notably, GI-related discontinuation was actually lower with tirzepatide (2.7%) than semaglutide (5.6%). Important caveat: the trial was open-label and used maximum tolerated dose rather than fixed dosing — real-world results may differ from this optimized setting.

Blood Sugar Control

Both medications powerfully lower HbA1c in patients with type 2 diabetes. Tirzepatide has demonstrated HbA1c reductions of up to 2.3 percentage points, compared to approximately 1.8 points for semaglutide. Both have shown the ability to bring a significant proportion of patients to an HbA1c below 5.7%, effectively in the non-diabetic range.

Side Effect Profiles

The side effect profiles are quite similar because both act on GLP-1 receptors. Gastrointestinal symptoms dominate.

• Nausea: Common with both, typically worst during dose escalation. Reported in 30-45% of patients.
• Vomiting: Slightly more common with tirzepatide at higher doses.
• Diarrhea: Reported more frequently with tirzepatide.
• Constipation: Reported more frequently with semaglutide.
• Injection-site reactions: Generally mild for both.
• Fatigue and headache: Reported at similar rates for both medications.

Serious adverse events are rare but include pancreatitis, gallbladder disease, and intestinal obstruction. Both carry a boxed warning about the theoretical risk of thyroid C-cell tumors based on animal studies.

Most GI side effects are transient, peaking during the first 2-4 weeks at a new dose and improving as the body adjusts. Slow titration significantly reduces the severity and duration of these symptoms.

Dosing and Administration

Both are once-weekly subcutaneous injections using pre-filled pens. Semaglutide titrates from 0.25 mg to a maximum of 2.4 mg (Wegovy) over about 16-20 weeks. Tirzepatide titrates from 2.5 mg to a maximum of 15 mg over a similar timeframe. Both can be injected in the abdomen, thigh, or upper arm.

Cost Comparison

At list price, both medications cost roughly $1,000-$1,350 per month without insurance. However, actual out-of-pocket costs depend heavily on insurance coverage, formulary placement, and manufacturer savings programs.

• Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) both offer savings cards for eligible commercially insured patients.
• Prior authorization is commonly required for both.
• Some insurers have preferred one over the other based on negotiated pricing.
• Generic versions are not yet available for either medication, though compounding pharmacies have offered semaglutide during shortage periods.

Which One Should You Choose?

The decision between semaglutide and tirzepatide depends on multiple factors.

• If maximizing weight loss is the priority and insurance covers both, tirzepatide has a slight edge in average results.
• If you are already stable on semaglutide and tolerating it well, switching may not be necessary.
• Insurance coverage and cost often become the deciding factor in practice.
• Your prescriber will also consider your cardiovascular history, diabetes status, and other health conditions.

Key Takeaways

Tirzepatide offers a dual-agonist mechanism that generally produces greater weight loss and HbA1c reduction than semaglutide in clinical trials. However, semaglutide has a longer track record, extensive cardiovascular outcomes data (SELECT trial), and broader availability. Both are safe, effective, and life-changing medications for the right patients. Work with your healthcare provider to determine which is the better fit for your situation.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.